NeuroPace, Inc. announced a first of its kind strategic collaboration that will leverage RNS System?s unique biomarker monitoring and data analysis capabilities. This collaboration will evaluate biomarker changes in currently implanted RNS System patients that have enrolled in a clinical-stage biotechnology company?s (company) clinical trial of its product candidate. Under the terms of the agreement, NeuroPace will make available certain information and insights about currently implanted RNS System patients that have also enrolled in the Company?s Phase 2a proof-of-concept study and consented to providing the Company data obtained through their RNS Systems. Information provided by NeuroPace will be used by the company to help them evaluate the impact of their product candidate on certain biomarkers of patients with focal onset seizures.

NeuroPace anticipates the total revenue from this collaboration to be approximately $3.7 million. The Agreement is broken out into four phases through the fourth quarter of 2025, with certain milestones correlating to each phase, the majority of which are planned to be completed prior to the end of 2024.